Lack of Data to Support ICI Retreatment in Advanced Melanoma
Immune checkpoint inhibitor retreatment in advanced melanoma is used in clinical practice, but there is a lack of evidence to support it.
United States University Of Chicago Castle Biosciences Daniel Olson Iovance Biotherapeutics Bristol Myers Squibb
Source: oncologynurseadvisor.com